-
Vatalanib is an inhibitor of VEGFR2/KDR. Vatalanib induces inhibition of the angiogenic response to VEGF and PDGF.
-
ENMD-1198 is an orally active microtubule-targeting agent with antiproliferative and antiangiogenic activity.
-
APG-1387 is a bivalent SMAC mimetic and an IAP antagonist. APG-1387 induces apoptosis with anti-cancer activity.
-
PU02, a derivative of 6-MP, is an allosteric antagonist of 5-HT3 receptor. PU02 possesses anti-cancer cativity by inducing aopotosis.
-
RJW100 is a potent LRH-1 and SF-1 agonist. RJW100 also causes strong activation of the miR-200c promoter and downregulates ZEB1 and ZEB2 proteins.
-
ZLDI-8 is an ADAM-17 inhibitor that makes tumor cells susceptible to anti-tumor agents and therefore overcoming the HCC multi-drug resistance process.
-
PI-103 is a potent PI3K and mTOR inhibitor, it also inhibits DNA-PK. PI-103 exhibits antiproliferative properties in a panel of human cancer cell lines.
-
CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus.
-
AC-73 is a first specific, orally active the cluster of differentiation 147 (CD147) inhibitor and specifically disrupts CD147 dimerization.
-
CGS 15943 is an orally bioavailable adenosine receptor antagonist with low nanomolar range Ki values for human A1, A2A, A2B, and A3 adenosine receptors.
Categories
Diseases
Others
Archives
- June 2022 (1)
- March 2021 (1)
- January 2021 (1)
- September 2020 (2)
- March 2020 (1)
- January 2020 (2)
- November 2019 (1)
- October 2019 (2)
- August 2019 (1)
- June 2019 (1)
- May 2019 (1)